A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Recruiting · Phase 2 · NCT06820463
Conditions: Metastatic Colorectal Cancer
At a glance
- Research payments reported, 2025
- $613,587
- U.S. investigators named
- 17
- Sites paid
- 15
- Planned or actual enrollment
- 390
About the trial
- Sponsor
- AbbVie
- Tested
- Telisotuzumab Adizutecan (drug), Fluorouracil (drug), Oxaliplatin (drug), Leucovorin (drug), Bevacizumab (drug), Panitumumab (drug)
- Dates
- Started 2025-04-24; completion 2028-04
- Results posted
- Not yet
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumu…
From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $613,587 in research payments for this study in 2025 (44 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Christina S. Wu, M.D. Hematology & Oncology · Scottsdale, AZ
- Gagandeep Brar, MD Hematology & Oncology · Mission Hills, CA
- Michael Cecchini, MD Hematology & Oncology · New Haven, CT
- Mohamedtaki A. Tejani, M.D. Medical Oncology · Orlando, FL
- Srilata Gundala, M.D. Hematology & Oncology · Hinsdale, IL
- Ardaman Shergill Medical Oncology · Chicago, IL
- Eejung Kim, MD Hematology · Boston, MA
- John C. Krauss, M.D. Medical Oncology · Ann Arbor, MI
- Zhaohui Jin, M.D. Medical Oncology · Rochester, MN
- Marc T. Roth, MD Hematology & Oncology · Kansas City, MO
- Hanna K. Sanoff, MD Hematology & Oncology · Chapel Hill, NC
- Timothy K. Huyck, M.D. Internal Medicine · Papillion, NE
- Mark E. Johns, MD Hematology & Oncology · Cincinnati, OH
- Marcia R. Cruz-correa, MD Gastroenterology · Rio Piedras, PR
- Vivian Cline, MD Medical Oncology · Round Rock, TX
- Pavel A. Levin, M.D., PH.D. Hematology & Oncology · Pearland, TX
- Chao Yin, MD Hematology & Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $149,573
- Sarah Cannon Research Institute LLC $58,500
- University of Michigan Health System, MI $48,745
- University of North Carolina $45,279
- Mayo Clinic Hospital, AZ $36,250
- Dana-Farber Cancer Institute $34,350
- Hope and Healing Cancer Services L $33,631
- The University of Chicago $31,200
- Virginia Cancer Specialists PC $30,719
- Pan American Center for Oncology $29,521
- St Lukes Hospital of Kansas City, MO $27,750
- Adventhealth Orlando, FL $24,380
- Mayo Clinic $22,250
- City of Hope National Medical Ctr $22,000
- Oncology Hematology West PC $19,440
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.